Loading…
Korean biopharma that developed and markets Xcopri (cenobamate), an epilepsy drug, directly in the US through its own subsidiary.
Korean biopharma that developed and markets Xcopri (cenobamate), an epilepsy drug, directly in the US through its own subsidiary.
Earns product sales of Xcopri directly in the US, and licence fees and royalties from partners that sell it elsewhere: in Europe Angelini Pharma markets it as Ontozry. Its own US sales team means it keeps the full revenue from its main market. Controlled by SK Inc., the Korean conglomerate's holding company.
Moat: narrow (IP / patents, regulatory licence). Patented epilepsy drug with FDA approval and its own US sales force, unusual for a Korean biopharma.
Headquarters: Seongnam, South Korea · Founded: 2011 · Employees: 272
Size SKBP (326030.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $5.12B, the 80th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩88,800 on 6 Nov 2026.
Performance Over six months the shares fell 11.1%, against +5.1% for the median peer and -24.5% for the South Korea market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue grew 38.9% over the last twelve months (peer median +10.7%); the operating margin is 35.2% (peer median 17.4%).
Valuation It trades at 21.6× forward earnings against a peer median of 33.1× (7th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +94%, so the hurdle is -93 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.4 points above its cost of capital (5.5% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩861B | ₩707B | ₩548B | ₩355B | ₩246B |
| Revenue growth | — | +29% | +54% | +44% | — |
| Gross profit | ₩798B | ₩652B | ₩492B | ₩308B | ₩197B |
| EBITDA | ₩319B | ₩221B | ₩114B | -₩22.8B | -₩118B |
| Net income | ₩401B | ₩267B | ₩241B | -₩32.9B | -₩139B |
| Free cash flow | ₩244B | ₩174B | ₩91.5B | -₩98.2B | -₩165B |
| Capital expenditure | ₩31.7B | ₩29.5B | ₩13.4B | ₩3.25B | ₩5.96B |
| Total debt | ₩48.8B | ₩48.9B | ₩184B | ₩178B | ₩156B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| SKBP 326030.KS | $5.12B | -11% | +39% | 35% | 21.6× | 0.5% |
| Jazz Pharmaceuticals Public JAZZ | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% |
| Eisai 4523.T | $8.68B | +4% | +7% | 5% | 24.2× | 11.8% |
| Supernus Pharmaceuticals SUPN | $5.43B | -49% | +16% | 45% | 6.7× | 4.2% |
| Xenon Pharmaceuticals XENE | $3.79B | +4% | -100% | n/a | n/a | n/a |
| Praxis Precision Medicines PRAX | $7.75B | -16% | -100% | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 326030.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.8% | +2.0% | 2nd highest of 20 |
| 6-month return | -11.1% | +5.1% | 7th lowest of 19 |
| Distance from 52-week high | -38.4% | -27.9% | 7th lowest of 21 |
| Revenue growth (TTM) | +38.9% | +10.7% | 4th highest of 18 |
| Operating margin | 35.2% | 17.4% | 4th highest of 18 |
| Forward P/E | 21.6× | 33.1× | 7th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 0.5% | 9.2% | 4th least demanding of 17 |
| Growth delivered (Del g) | +93.6% | +10.9% | highest of 17 |
| Hurdle (Req g minus delivered) | -93.1 pp | -3.3 pp | least demanding of 17 |
| ROIC minus cost of capital | +16.4 pp | +2.9 pp | 4th highest of 16 |
| EV / EBITDA | 21.8× | 17.4× | 5th most expensive of 11 |
| Net debt / EBITDA | -1.0× | 0.1× | 6th least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SKBP 326030.KS | South Korea | $5.12B | -11% | +39% | 35% | 21.6× | 0.5% | +93.6% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $5.18B | -39% | +14% | 11% | 41.6× | 15.5% | +9.7% |
| Erasca ERAS | United States | $5.04B | +42% | n/a | n/a | n/a | n/a | n/a |
| IPCA Laboratories IPCALAB.NS | India | $5.22B | +24% | +11% | 17% | 32.4× | 17.8% | +12.2% |
| Sumitomo Pharma 4506.T | Japan | $5.23B | +7% | +11% | 10% | 8.3× | 1.4% | -2.6% |
| Beijing TongRenTang 600085.SS | China | $5.27B | -8% | -17% | 8% | 31.2× | 2.7% | +6.2% |
| Supernus Pharmaceuticals SUPN | United States | $5.43B | -49% | +16% | 45% | 6.7× | 4.2% | +13.9% |
| Novast Laboratories 301569.SZ | China | $4.82B | n/a | +3% | 27% | n/a | 42.6% | +3.1% |
| PTC Therapeutics PTCT | United States | $5.47B | -11% | -35% | 22% | 34.8× | 8.0% | +35.4% |
| Travere Therapeutics TVTX | United States | $4.76B | +16% | +49% | -3% | 16.9× | 16.7% | +19.9% |
| Gland Pharma GLAND.NS | India | $5.53B | +69% | +18% | 20% | 39.0× | 28.0% | +13.3% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% | +3.0% |
| Apotex Health APTX.TO | Canada | $5.62B | n/a | +4% | 32% | 18.6× | -13.5% | +4.2% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | China | $4.61B | -11% | +1% | 3% | 13.3× | -0.3% | +4.7% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $4.53B | -17% | +60% | -4% | 64.5× | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 35.9× | 25.2% | +5.5% |
| Veradermics MANE | United States | $5.80B | +31% | n/a | n/a | n/a | n/a | n/a |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 48.5× | 10.4% | +46.5% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 33.9× | 14.9% | +12.7% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 46.9× | 3.3% | +45.1% |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |